Manufacturing In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Pharmaceutical TechnologyIn 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.ManufacturingRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers. ManufacturingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay OffNext: CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment Related Stories Manufacturing pharminent June 17, 2026 Manufacturing Eisai claims UK grant to expand manufacturing site pharminent June 15, 2026 Manufacturing FDA imposes import alert on Indian plant after inspectors flag GMP failings pharminent June 12, 2026
